HONG KONG: A new anti-viral drug to treat both bird and human flu, developed by US-based BioCryst Pharmaceuticals, will be tested across Asia next month, the pharmacist involved in the trial in Hong Kong said yesterday.
In an earlier animal trial, the drug, peramivir, boosted the survival rates of mice and ferrets infected with the H5N1 bird flu virus. Some experts say it could be the next-line drug to fight all types of influenza, including H5N1.
The trial will involve people seeking treatment for seasonal influenza in Hong Kong, Singapore, New Zealand and Australia. Half of them will be given peramivir, and the other half a conventional, orally-administered flu drug. Peramivir is a parenteral, or intravenous, anti-viral drug.
“They (BioCryst) will compare which (drug) is better, parenteral or oral, to see which one cures faster, which (type of administration) brings viral loads down faster,” said William Chui of the University of Hong Kong’s Clinical Trials Centre.
Roche Holding AG’s Tamiflu is considered the first line of defence against bird flu, although early treatment — within 48 hours of the first signs of symptoms — is pivotal. A death rate of up to 60% has spurred the search for other drugs and vaccines to fight the H5N1 strain.
“In a pandemic, having an oral treatment may not be enough because intravenous treatment is more efficacious,” said Chui. “Having the drug injected means it goes straight to the bloodstream … so if you administer at the 48th hour, the body can still benefit, but an oral dose will take time to get into the blood. There will be a time lag,” Chui explained. “You have to be fast if you want to curb viral replication. Once after 48 hours, the viral load will be very high, and it will be very tough (to get rid of them).”